MAPK3 and cancer: In addition, our pharmacological inhibition of ERK1/2 by SCH772984 and genetic knockdown of ERK1/2 using shRNAs corroborate each other to strengthen our finding of the regulatory association between the EGF–ERK1/2 signaling pathways and glucosome assemblies in cancer cells.